Industry veteran brings extensive experience leading biotech companies through periods of growth WALTHAM, Mass.– Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Joshua Brumm as President and Chief Executive Officer. “Josh brings extraordinary skills and experience to further our mission of creating life-transforming therapies for patients with serious muscle diseases,” said Jason Rhodes, partner with Atlas Venture and Dyne founder and executive chairman of the board of directors. “This positions us strongly to pursue the next phase of growth and product development, and we are thrilled to have him joining us.” “Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Joshua Brumm. “I look forward to working closely with the board and talented team at Dyne to maximize the potential of our platform by advancing our pipeline and exploring new partnerships.” “On behalf of everyone here, I am excited to welcome Josh,” said Romesh Subramanian, Dyne founder and chief scientific officer. “We look forward to working together to realize the therapeutic power of oligonucleotides for patients with rare muscle diseases and fulfilling Dyne’s mission.” Prior to joining Dyne, Mr. Brumm served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Mr. Brumm has raised approximately $1 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass. For more information, please visit www.dyne-tx.com.
How do I contact Joshua T. Brumm?
Has Joshua T. Brumm been buying or selling shares of Dyne Therapeutics?
Who are Dyne Therapeutics' active insiders?
Are insiders buying or selling shares of Dyne Therapeutics?
During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 1,746,285 shares worth more than $31,057,267.50. During the last year, insiders at the sold shares 48 times. They sold a total of 2,547,573 shares worth more than $62,638,020.82. The most recent insider tranaction occured on December, 11th when insider Oxana Beskrovnaya sold 2,334 shares worth more than $65,632.08. Insiders at Dyne Therapeutics own 20.8% of the company.
Learn More about insider trades at Dyne Therapeutics. Information on this page was last updated on 12/11/2024.
